Recommendations for Influenza Vaccination in Burns Patients Based on a Systematic Review of the Evidence.
Journal
Journal of burn care & research : official publication of the American Burn Association
ISSN: 1559-0488
Titre abrégé: J Burn Care Res
Pays: England
ID NLM: 101262774
Informations de publication
Date de publication:
05 01 2022
05 01 2022
Historique:
pubmed:
9
3
2021
medline:
8
3
2022
entrez:
8
3
2021
Statut:
ppublish
Résumé
Severe burn injury is a serious systemic insult that can lead to life-threatening secondary infections. Immunosuppression, inhalation injury, and prolonged length of hospital stay are factors that predispose patients to severe respiratory tract infections. Furthermore, evidence shows that burns can put one at risk of infection long after the original injury. Currently in the United Kingdom, the annual National Flu Immunisation programme outlines guidance for groups who are deemed high risk and, therefore, eligible for the influenza vaccine. At present, no guidance exists for the administration of the influenza vaccine in burn-injured patients, despite knowledge of immunosuppression. The aim of this literature review is to examine the evidence for associations between burn injury and influenza and, where available, evaluate efficacy of influenza vaccines in this cohort. In addition, literature was searched for the effectiveness of the influenza vaccine in patients 65 years and above and in patients admitted to the intensive care unit (ICU), two domains common to patients with severe burns. Three papers were found to suggest increased susceptibility to influenza following burn injury; however, no papers studying the effectiveness of the influenza vaccine in this group were found. Several studies demonstrated improved outcomes in patients over 65 years and patients admitted to ICU. Following the evaluation of the evidence, this review advocates for the consideration of hospitalized burn patients for the influenza vaccine. We suggest the avoidance of vaccine administration in the acute burn phase. Further prospective clinical trials would be required to validate these findings.
Identifiants
pubmed: 33682002
pii: 6157892
doi: 10.1093/jbcr/irab043
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-103Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.